NASDAQ:BBIO BridgeBio Pharma (BBIO) Stock Price, News & Analysis → Never use this word on your phone (FBI could be watching) (From Paradigm Press) (Ad) Free BBIO Stock Alerts $27.83 +0.09 (+0.32%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$27.17▼$28.7850-Day Range$24.33▼$35.7352-Week Range$12.75▼$44.32Volume1.68 million shsAverage Volume1.57 million shsMarket Capitalization$5.21 billionP/E RatioN/ADividend YieldN/APrice Target$47.82 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get BridgeBio Pharma alerts: Email Address BridgeBio Pharma MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside71.8% Upside$47.82 Price TargetShort InterestBearish10.86% of Float Sold ShortDividend StrengthN/ASustainability-2.31Upright™ Environmental ScoreNews Sentiment0.51Based on 10 Articles This WeekInsider TradingSelling Shares$85,000 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.09) to ($2.76) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.51 out of 5 starsMedical Sector517th out of 5,424 stocksPharmaceutical Preparations Industry163rd out of 2,550 stocks 4.4 Analyst's Opinion Consensus RatingBridgeBio Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageBridgeBio Pharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.86% of the float of BridgeBio Pharma has been sold short.Short Interest Ratio / Days to CoverBridgeBio Pharma has a short interest ratio ("days to cover") of 8.9.Change versus previous monthShort interest in BridgeBio Pharma has recently increased by 5.53%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBridgeBio Pharma does not currently pay a dividend.Dividend GrowthBridgeBio Pharma does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBridgeBio Pharma has received a 53.04% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Infigratinib", "Fosdenopterin", and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for BridgeBio Pharma is -2.31. Previous Next 1.9 News and Social Media Coverage News SentimentBridgeBio Pharma has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for BridgeBio Pharma this week, compared to 5 articles on an average week.Search InterestOnly 9 people have searched for BBIO on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added BridgeBio Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -53% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BridgeBio Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $85,000.00 in company stock.Percentage Held by Insiders28.52% of the stock of BridgeBio Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.85% of the stock of BridgeBio Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BridgeBio Pharma are expected to grow in the coming year, from ($3.09) to ($2.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BridgeBio Pharma is -8.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BridgeBio Pharma is -8.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About BridgeBio Pharma Stock (NASDAQ:BBIO)BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Read More BBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BBIO Stock News HeadlinesMay 3, 2024 | finance.yahoo.comBridgeBio Pharma First Quarter 2024 Earnings: Beats ExpectationsMay 3, 2024 | markets.businessinsider.comBuy Rating Affirmed: BridgeBio Pharma’s Growth Trajectory Bolstered by Strong Pipeline and Strategic InitiativesMay 5, 2024 | Paradigm Press (Ad)Never use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...May 2, 2024 | sfgate.comBridgeBio Pharma: Q1 Earnings SnapshotMay 2, 2024 | globenewswire.comBridgeBio Pharma Reports First Quarter 2024 Financial Results and Business UpdateMay 2, 2024 | americanbankingnews.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Short Interest UpdateMay 1, 2024 | americanbankingnews.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Average Rating of "Moderate Buy" from BrokeragesApril 30, 2024 | markets.businessinsider.comMaintaining Buy Rating on BridgeBio Pharma: Undervalued Potential of Acoramidis Amid Market UnderperformanceMay 5, 2024 | Paradigm Press (Ad)Never use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...April 20, 2024 | uk.investing.comBridgeBio Pharma Inc (BBIO)April 11, 2024 | finance.yahoo.comBridgeBio Pharma, Inc. (BBIO)April 10, 2024 | globenewswire.comBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 10, 2024 | globenewswire.comBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for BridgeBio Pharma on Acoramidis’ Positive ATTR-CM Trial OutcomesApril 7, 2024 | globenewswire.comBridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)March 25, 2024 | markets.businessinsider.comBuy Rating Justified for BridgeBio Pharma Amidst Promising Long-Term Market Prospects for ATTR-CM TreatmentsMarch 22, 2024 | seekingalpha.comBridgeBio Pharma: Assessing Acoramidis' Market Opportunity, Further Upside Potential EvidentMarch 20, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Jazz Pharmaceuticals (JAZZ)March 20, 2024 | globenewswire.comBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)March 19, 2024 | finance.yahoo.comBBIO Mar 2024 32.000 callMarch 17, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - BBIOMarch 16, 2024 | finance.yahoo.comBBIO Mar 2024 30.000 callMarch 16, 2024 | ca.finance.yahoo.comBBIO Mar 2024 30.000 putMarch 9, 2024 | finance.yahoo.comBBIO Mar 2024 25.000 putMarch 9, 2024 | ca.finance.yahoo.comBBIO Mar 2024 31.000 callMarch 7, 2024 | ca.finance.yahoo.comBBIO Mar 2024 25.000 callMarch 6, 2024 | uk.investing.comBridgeBio Pharma launches $250 million stock offeringSee More Headlines Receive BBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BridgeBio Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today5/04/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BBIO CUSIPN/A CIK1743881 Webbridgebio.com Phone(650) 391-9740FaxN/AEmployees550Year FoundedN/APrice Target and Rating Average Stock Price Target$47.82 High Stock Price Target$70.00 Low Stock Price Target$33.00 Potential Upside/Downside+71.8%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($3.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-643,200,000.00 Net Margins-246.24% Pretax Margin-7,021.94% Return on EquityN/A Return on Assets-90.03% Debt Debt-to-Equity RatioN/A Current Ratio3.32 Quick Ratio3.32 Sales & Book Value Annual Sales$9.30 million Price / Sales559.98 Cash FlowN/A Price / Cash FlowN/A Book Value($7.72) per share Price / Book-3.60Miscellaneous Outstanding Shares187,130,000Free Float133,760,000Market Cap$5.21 billion OptionableOptionable Beta1.08 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Neil Kumar Ph.D. (Age 45)Co-Founder, President, CEO & Director Comp: $2.1MDr. Charles J. Homcy M.D. (Age 76)Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director Comp: $208kDr. Brian C. Stephenson C.F.A. (Age 43)Ph.D., CFO & Secretary Comp: $1.15MDr. Richard H. Scheller Ph.D. (Age 71)Chairman of Research & Development Comp: $202.4kDr. Frank P. McCormick Ph.D. (Age 74)Co-Founder, Chairman of Oncology & Director Dr. Uma Sinha Ph.D. (Age 66)Chief Scientific Officer Comp: $1.31MGrace RauhVice President of CommunicationsMr. Eli M. Wallace Ph.D. (Age 57)Chief Scientific Officer of Oncology Dr. Thomas Trimarchi Ph.D.Chief Product OfficerDr. Eric Michael David J.D. (Age 52)M.D., Ph.D., Chief Executive Officer of Gene Therapy More ExecutivesKey CompetitorsOrganon & Co.NYSE:OGNPerrigoNYSE:PRGONuvalentNASDAQ:NUVLApellis PharmaceuticalsNASDAQ:APLSAlpine Immune SciencesNASDAQ:ALPNView All CompetitorsInsiders & InstitutionsCapstone Investment Advisors LLCBought 83,540 shares on 5/1/2024Ownership: 0.045%Mirae Asset Global Investments Co. Ltd.Sold 4,029 shares on 5/1/2024Ownership: 0.033%Principal Financial Group Inc.Bought 129,703 shares on 4/29/2024Ownership: 0.573%China Universal Asset Management Co. Ltd.Bought 13,654 shares on 4/29/2024Ownership: 0.018%YHB Investment Advisors Inc.Bought 1,090 shares on 4/26/2024Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions BBIO Stock Analysis - Frequently Asked Questions Should I buy or sell BridgeBio Pharma stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BridgeBio Pharma in the last twelve months. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BBIO shares. View BBIO analyst ratings or view top-rated stocks. What is BridgeBio Pharma's stock price target for 2024? 10 brokers have issued 12-month target prices for BridgeBio Pharma's shares. Their BBIO share price targets range from $33.00 to $70.00. On average, they expect the company's stock price to reach $47.82 in the next twelve months. This suggests a possible upside of 71.8% from the stock's current price. View analysts price targets for BBIO or view top-rated stocks among Wall Street analysts. How have BBIO shares performed in 2024? BridgeBio Pharma's stock was trading at $40.37 at the beginning of 2024. Since then, BBIO shares have decreased by 31.1% and is now trading at $27.83. View the best growth stocks for 2024 here. Are investors shorting BridgeBio Pharma? BridgeBio Pharma saw a increase in short interest in April. As of April 15th, there was short interest totaling 15,070,000 shares, an increase of 5.5% from the March 31st total of 14,280,000 shares. Based on an average trading volume of 1,690,000 shares, the short-interest ratio is currently 8.9 days. Approximately 10.9% of the shares of the stock are sold short. View BridgeBio Pharma's Short Interest. When is BridgeBio Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our BBIO earnings forecast. How were BridgeBio Pharma's earnings last quarter? BridgeBio Pharma, Inc. (NASDAQ:BBIO) announced its earnings results on Thursday, February, 22nd. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.87) by $0.09. The company earned $1.74 million during the quarter, compared to analysts' expectations of $4.78 million. BridgeBio Pharma's revenue for the quarter was down 8.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.92) earnings per share. What ETFs hold BridgeBio Pharma's stock? ETFs with the largest weight of BridgeBio Pharma (NASDAQ:BBIO) stock in their portfolio include Tema Cardiovascular and Metabolics ETF (HRTS), WisdomTree BioRevolution Fund (WDNA), Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Franklin Genomic Advancements ETF (HELX) and Invesco Nasdaq Biotechnology ETF (IBBQ). What other stocks do shareholders of BridgeBio Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other BridgeBio Pharma investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Pfizer (PFE), Roku (ROKU), Editas Medicine (EDIT), Block (SQ), Sorrento Therapeutics (SRNE) and Sarepta Therapeutics (SRPT). When did BridgeBio Pharma IPO? BridgeBio Pharma (BBIO) raised $225 million in an initial public offering on Thursday, June 27th 2019. The company issued 15,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink and KKR acted as the underwriters for the IPO and Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James were co-managers. Who are BridgeBio Pharma's major shareholders? BridgeBio Pharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Principal Financial Group Inc. (0.57%), Portman Square Capital LLP (0.00%), WCM Investment Management LLC (0.10%), Hennion & Walsh Asset Management Inc. (0.08%), Capstone Investment Advisors LLC (0.04%) and Mirae Asset Global Investments Co. Ltd. (0.03%). Insiders that own company stock include Brian C Stephenson, Douglas A Dachille, Frank Mccormick, Global Investors Lp Viking, Hannah Valantine, Neil Kumar, Randal W Scott, Richard H Scheller and Ronald J Daniels. View institutional ownership trends. How do I buy shares of BridgeBio Pharma? Shares of BBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BBIO) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe only AI company you should be looking atBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
